What You Should Know:
– MoldCo, a telehealth platform specializing in the diagnosis and treatment of mold and environmental toxins, has announced it has raised $8M in seed funding co-led by Cantos and Collaborative Fund. The funding brings the company’s total funding to $11M.
– The funding will be used to expand MoldCo’s virtual clinic and advance its mission to make expert-led care for mold-related illness more affordable and accessible to patients nationwide.
Mold: The Invisible Crisis in American Homes
According to the data, more than 50% of U.S. households show signs of mold, water damage, or dampness. Despite this, most physicians do not screen for or treat mold-related illness, leading to a significant gap in care. People who suffer from mold exposure often spend years and thousands of dollars searching for an explanation, cycling through specialists and misdiagnoses. Mold toxicity can trigger serious long-term symptoms, including Chronic Inflammatory Response Syndrome (CIRS), which is frequently mistaken for chronic fatigue, fibromyalgia, or anxiety.
Evidence-Based Care for Mold Toxicity
MoldCo provides a scalable telehealth platform that offers patients immediate access to evidence-based care for mold toxicity. The treatment averages just $150–$300 per month, which is significantly less than the fragmented and often ineffective alternatives that can cost tens of thousands of dollars. The company’s founder and CEO, Ariana Thacker, noted that MoldCo was born from her own frustrating experience with conventional medicine while battling severe mold illness.
“It revealed a critical gap: individuals are suffering because the specialized knowledge needed to diagnose and treat these conditions is widely unavailable. MoldCo was born from that experience. By combining specialized clinical expertise with telehealth accessibility, we’re making evidence-based care available to everyone who needs it as quickly as possible, at a fraction of the current cost,” said Ariana Thacker, MoldCo founder and CEO.
The platform streamlines the process into three simple steps for patients to get clarity on their symptoms, access virtual care, and receive treatments delivered to their home. This includes direct access to certified specialists, advanced lab testing, evidence-based treatments, and 24/7 support from care navigators.
Expanding Network of Specialized Clinicians
With the new funding, MoldCo plans to expand its network of specialized clinicians across the U.S., develop its proprietary care technology, and invest in clinical research collaborations. The company aims to standardize mold detox as a crucial part of routine care, making it as common as a physical or dental exam. MoldCo is currently offering advanced lab testing in 46 states and providing care in select states, with plans to be available nationwide by 2026.
